All In Biotech

Drug Trial Radar · NCT04574869

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, PK, & PD of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 2021

Primary completion

Sep 2022

Study completion Dec 2022

Sponsor

Lead sponsor
ReAlta Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory failure. Patients will be randomized and double-blinded for two parts, a single-ascending dose (SAD) part and a multiple-ascending dose (MAD) part. The name of the study drug involved in this study is: RLS-0071.

Conditions

  • Acute Lung Injury
  • ALI
  • COVID-19

Interventions

  • RLS-0071 10 mg/kgDrug

    Single dose IV infusion of 10 mg/kg RLS-0071

  • RLS-0071 40 mg/kgDrug

    Single dose IV infusion of 40 mg/kg RLS-0071

  • PlaceboDrug

    The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).

  • RLS-0071 10 mg/kgDrug

    Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)

  • RLS-0071 40 mg/kgDrug

    Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events.Time frame: Through study completion at Day 28 following last dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henry Ford Health Systems

    Detroit, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.